ArticleMolecular neurodegeneration2017
Diurnal oscillation of CSF Aβ and other AD biomarkers.
Article in Molecular neurodegeneration, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 40 citations in OpenAlex.
- Fluid Biomarkers of Disease Burden and Cognitive Dysfunction in Progressive Supranuclear Palsy.Annals of clinical and translational neurology · 2026Article
- Pre-analytical guidelines for blood and CSF Biomarkers 2025: Recommendations from the NACC ADRC Biofluid Biomarker Best Practices Workgroup.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- Wake-promoting neuromodulators in Alzheimer's disease: Implications for sleep and brain clearance.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- Diagnostic performance of plasma p-tau217 and Aβ42/40 biomarkers in the outpatient memory clinic.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Combining cerebrospinal fluid and PI-2620 tau-PET for biomarker-based stratification of Alzheimer's disease and 4R-tauopathies.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- P-tau217 and other blood biomarkers of dementia: variation with time of day.Translational psychiatry · 2024Article
- Amyloid-β but not tau accumulation is strongly associated with longitudinal cognitive decline.CNS neuroscience & therapeutics · 2024Article
- Effects of time of the day at sampling on CSF and plasma levels of Alzheimer' disease biomarkers.Alzheimer's research & therapy · 2024Article
- Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches.Journal of extracellular vesicles · 2024Article
- Understanding the Episodic Memory and Executive Functioning Axis Impairment in MCI Patients: A Multicenter Study in Comparison with CSF Biomarkers.Biomedicines · 2023Article
- The Alzheimer's disease-linked protease BACE1 modulates neuronal IL-6 signaling through shedding of the receptor gp130.Molecular neurodegeneration · 2023Article
- Nanowired Delivery of Cerebrolysin Together with Antibodies to Amyloid Beta Peptide, Phosphorylated Tau, and Tumor Necrosis Factor Alpha Induces Superior Neuroprotection in Alzheimer's Disease Brain Pathology Exacerbated by Sleep Deprivation.Advances in neurobiology · 2023Review
- Establishment of combined diagnostic models of Alzheimer's disease in a Chinese cohort: the Chongqing Ageing & Dementia Study (CADS).Translational psychiatry · 2022Article
- Cross-sectional and longitudinal association of sleep and Alzheimer biomarkers in cognitively unimpaired adults.Brain communications · 2022Article
- Circadian rhythms in neurodegenerative disorders.Nature reviews. Neurology · 2022Review
- 2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.European journal of nuclear medicine and molecular imaging · 2021Review
- Pimavanserin, a 5HTJournal of neurochemistry · 2021Article
- Metabolic Disturbances Induced by Sleep Restriction as Potential Triggers for Alzheimer's Disease.Frontiers in integrative neuroscience · 2021Review
- Circadian Clocks, Sleep, and Metabolism.Advances in experimental medicine and biology · 2021Article
- Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies.Nature communications · 2020Article
Corrections and comments
- Comment on
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
To assess stages of Alzheimer's disease (AD) pathogenesis and the efficacy of drugs during clinical trials, there has been immense interest in the field to establish baseline cerebrospinal fluid (CSF) concentrations for potential AD biomarkers such as amyloid-β (Aβ) and tau. Significant within-person variations in CSF Aβ concentrations over time found that this variation followed the sleep-wake cycle. A recent paper in Molecular Neurodegeneration reported the absence of diurnal variations in multiple classical and candidate AD biomarkers, such as soluble APP, Aβ, tau, p-tau, YKL-40, VILIP-1, or apolipoprotein E. This commentary addresses these apparently discordant results regarding the diurnal variability of APP and Aβ compared with the literature. Despite our concerns, we appreciate the authors' interest in this important topic and contribution to improve our knowledge about the factors influencing Aβ diurnal variation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.